Switzer TV

 

In our last episode of 2025, we get the heavy hitters. This week on Switzer Investing TV, Peter Switzer sits down with three seasoned market pros to cut through the noise and talk straight about where the real growth opportunities may lie heading into 2026.

With tech stocks sold off, resources rotating back into favour, and AI fears dominating headlines, each guest lays out what they’d actually buy now and why.

Adam Dawes kicks things off by explaining why selective commodities, developers and beaten-up growth names are back on the radar, and where investors need to be careful.

Jun Bei Liu then shares her “buy low” Christmas gift ideas, focusing on high-quality growth companies that have fallen out of favour but continue to grow earnings. Finally, Paul Rickard wraps up the year with a pragmatic take on oversold tech, patience, and which names could reward investors willing to look past short-term fear.

Interview timecodes:

00:01:01 - Adam Dawes, Shaw and Partners

00:17:41 - Jun Bei Liu, TenCap

00:25:37 - Paul Rickard, Switzer Report

 

This is our last show for 2025. We thank you for joining us and we'll see you on 10 January, 2026 with a new year of Switzer Investing TV.

Switzer Investing TV (15/12/25): What would our experts invest in now for growth in 2026?

In our last episode of 2025, we get the heavy hitters. This week on Switzer Investing TV, Peter Switzer sits down with three seasoned market pros to cut through the noise and talk straight about where the real growth opportunities may lie heading into 2026.

More videos

Peter Cook from Novatti Group (ASX:NOV)

Peter Switzer sits down with the CEO of Novatti (NOV), Peter Cook.

Series:
Another new treatment for Glioblastoma

Dr Ross Walker talks about another new trial into treating Glioblastoma, one of the most aggressive brain cancers.

Series:
Will HospoKeeper replace JobKeeper?

Peter Switzer and Paul Rickard look at the potential replacements to JobKeeper, why Wall Street likes Joe Biden and what JB Hi-Fi's strong sales numbers mean for the economy.

Series:
Dr Chris Hart from Oventus Medical (ASX:OVN)

Peter Switzer speaks to the founder and CEO of Oventus (OVN), Dr Chris Hart.

Series:
BUY or SELL these hot stocks: Tyro, Z1P, A2M, ELO, EML, TWE, NXT and MP1

On this week's show, Peter Switzer is joined by Fairmont Equities' Michael Gable, Burman Invest's Julia Lee, Switzer's Paul Rickard and Avecho's Dr Paul Gavin.

Series:
Brian Ward from Aroa Biosurgery (ASX:ARX)

Peter Switzer is joined by Brian Ward, the founder and CEO of soft tissue regeneration company Aroa (ARX).

Series:
Two new treatments for Glioblastoma

Dr Ross Walker explains two studies that are finding new treatments for Glioblastoma, one of the most devastating kinds of brain tumour.

Series:
Peter Switzer & Paul Rickard look at the stocks they like for 2021

Peter and Paul take a look back on 2020 and look ahead to the stocks that will do well in 2021, plus highlights from an interview with technology entrepreneur Bevan Slattery.

Series:
Julia Lee & Jun Bei Liu gives you the stocks they really love!

Get ready for investing in 2021 with Peter Switzer, Julia Lee from Burman Invest and Jun Bei Liu from Tribeca Investment Partners, plus an interview with JB Hi-Fi CEO Richard Murray.

Series:
CEOs of Webjet and ELMO talk up their stocks

Peter Switzer shines the spotlight on Webjet and ELMO Software, plus Adam Dawes from Shawn and Partners takes a look at some stocks.

Series:
15 stocks you have to consider for 2021! Is Mesoblast one of them?

Burman Invest's Julia Lee and Switzer's Paul Rickard join Peter Switzer.

Series:
How to combat the overprescription of medication

Dr Ross Walker looks at why overprescription is happening and why you should talk to your doctor about the medications you are on.

Series: ,
1 36 37 38 39 40 51

Fill in the form below to subscribe to Switzer Daily and get our latest articles, videos and podcasts sent straight to your inbox

Get the latest financial, business, and political expert commentary delivered to your inbox.

When you sign up, we will never give away or sell or barter or trade your email address.

And you can unsubscribe at any time!
Subscribe
© 2006-2021 Switzer. All Rights Reserved. Australian Financial Services Licence Number 286531. 
shopping-cartphoneenvelopedollargraduation-cap linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram